Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors

This study is testing GT201 — a personalized immune cell therapy made from your own tumor-fighting cells — combined with a checkpoint inhibitor (PD-1 inhibitor) for advanced or returning head and neck cancers. **You may be eligible if...** - You are between 18 and 70 years old - You have been diagnosed with recurrent or metastatic head and neck cancer - You have received no more than 2 prior lines of cancer treatment - You have at least one tumor that can be safely sampled for cell preparation - Your general health and organ function meet study requirements **You may NOT be eligible if...** - You have had a severe autoimmune disease or require immune-suppressing medications - You have active, uncontrolled infections - Your heart, liver, kidney, or lung function is significantly impaired - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.